Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont Oral TNF Inhibitor For Arthritis, Sustiva Successor Are In Phase II

Executive Summary

DuPont Pharmaceuticals expects to file an NDA for an orally dosed TNF inhibitor in 2004, the company told analysts April 11.
Advertisement

Related Content

Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line
Bristol/DuPont Is Timely Deal: Will Disrupt Difficult 2002, Add To 2003
Bristol/DuPont Is Timely Deal: Will Disrupt Difficult 2002, Add To 2003
Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line
DuPont Pharma Has "A Number Of Bidders"; Company Still Considering IPO
DuPont Pharma Has "A Number Of Bidders"; Company Still Considering IPO
DuPont Pharma Has "A Number Of Bidders"; Company Still Considering IPO
Knoll Takeover Value Hinges On Outlook For D2E7 Rheumatoid Arthritis Agent
Advertisement
UsernamePublicRestriction

Register

PS037649

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel